Search results
Results from the WOW.Com Content Network
Bamlanivimab and etesevimab, administered together, are authorized in the United States for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 ...
On 9 November 2020, bamlanivimab was granted an emergency use authorization by the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults and adolescents. Bamlanivimab is authorized for people with positive results of direct SARS-CoV-2 viral testing who are twelve years of age and older weighing at least ...
Vaccine combinations (few exceptions), antibiotics, low-dose steroids (less than 20 mg per day), minor infections with low fever (below 38.5º Celsius), diarrhea, malnutrition, kidney or liver disease, heart or lung disease, non-progressive encephalopathy, well controlled epilepsy or advanced age, are not contraindications to vaccination.
AD5-nCOV, trade-named Convidecia, is a single-dose [2] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics , with Phase III trials conducted in Argentina , [ 3 ] Chile , [ 4 ] Mexico , [ 5 ] Pakistan , [ 6 ] Russia , [ 7 ] and Saudi Arabia [ 8 ] with 40,000 participants.
The Philippines has received 100,000 doses of the Sinopharm BIBP vaccine from the United Arab Emirates. [102] The Philippines has received a donation of about 1,000,000 doses of the Sinopharm BIBP vaccine on August 20–21 from China. [103] [104] The Philippines has expressed its intent to get some of Canada's COVID-19 vaccines. [105]
Comparing data from 2014 between Philippines, United States of America, and Canada, Philippines only spent 4.7% of their GDP on health while USA and Canada spent 17.1% and 10.4%. [2] [3] [4] Efforts are being performed to bridge the gap. On February 20, 2019, the Universal Health Care (UHC) Bill was signed into law, aiming to provide proper ...
As of September 2020, the Philippines has a population of nearly 110 million and a population density of 368 per square kilometer. 32% of the population of the Philippines is under 15 years old, and only 22.2% is over 60. In the Philippines, 16.6% of the population lived below the national poverty line in 2018. [8] [9]
On 15 October, the Beijing Institute of Biological Products published results of its Phase I (192 adults) and Phase II (448 adults) clinical studies for the BIBP vaccine, showing it to be safe and well-tolerated at all tested doses in two age groups. Antibodies were elicited against SARS-CoV-2 in all vaccine recipients on day 42. These trials ...